We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).

We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.

Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.

Advanced search
Date range (dd-mm-yyyy)

Allergy Therapeutics

VLP Peanut heading towards US Phase I studies

Update | 21 September 2021

Redx Pharma

ESMO 2021: RXC004 monotherapy Phase I study results

Update | 21 September 2021

Arecor Therapeutics

AT278 Phase I delivers better than expected results

Lighthouse | 20 September 2021

Arecor Therapeutics

Formulating the recipe for success

Initiation | 14 September 2021

Redx Pharma

Kadmon acquisition has read across for RXC007

Lighthouse | 08 September 2021

Redx Pharma

All that Jazz: $3m milestone boosts cash and confidence

Update | 07 September 2021


Accelerated protocols could be a game changer

Outlook | 19 August 2021


Lead therapeutic asset AVA6000 enters the clinic

Lighthouse | 11 August 2021


Strategic collaboration for Tazverik in Greater China

Lighthouse | 10 August 2021

Allergy Therapeutics

Biomarker data confirm VLP Peanut hypoallergenicity

Lighthouse | 03 August 2021
1 2 3 4 5 6 7 8 9 10 >
311 results found.